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Abstract Objective: This study explores the synergistic ef-
fect of cardiomyoblast apoptosis induced by angiotensin II
(Ang II) and Insulin-like growth factor (IGF)-I resistance,
and elucidates the role of IGF-II via IGF-II receptor (R) and
calcineurin pathways in apoptosis induced by Ang II and
IGF-I resistance. Methods: Apoptosis of cultured cardiomy-
oblast H9c2 cells was assessed by DNA fragmentation on
agarose gel electrophoresis, nuclear condensation stained
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with DAPI, and Western blot analysis of pro-apoptotic
Bad and cytochrome c in various combinations of control,
Ang II, antisense IGF (I or II), IGF (I or II) antibody, IGF
(I or II) receptor (R) antibody, or calcineurin inhibitor (Cy-
closporine A, (CsA)). Results: We found the following: (1)
The combination of Ang II and IGF-I deficiencies had a
synergistic effect on apoptosis, confirmed by DNA frag-
mentation, nuclei condensation, and increases in such pro-
apoptotic proteins as Bad, cytochrome c, caspase 9, and cas-
pase 3 in H9c2 cells. (2) IGF-II and IGF-IIR protein products
were increased by antisense IGF-I and IGF-I resistance, but
these IGF-II protein products were not affected by sense
IGF-I and non-specific antibody IgG in H9c2 cells. (3) The
alteration of Bad protein level and the release of cytochrome
c, both induced by treatments containing combinations of
Ang II and antisense IGF-I, IGF-I antibody or IGF-IR anti-
body, were inhibited by IGF-II antibody. (4) DNA fragmen-
tation, Bad, and cytochrome c which was induced by treat-
ments combining IGF-IR antibody with Ang II or combining
IGF-IR antibody with IGF-II were remarkably attenuated by
CsA. Conclusion: IGF-I deficiency and/or IGF-IR resistance
induced apoptosis in cardiomyoblast cells. The apoptosis,
which might have been caused by the upregulation of IGF-II
and IGF-IIR genes possibly activated the downstream cal-
cineurin pathway, was synergistically augmented by Ang II.
Keywords IGF-I resistance . Angiotensin II . Calcineurin .
IGF-II . Cardiomyoblast apoptosis
Introduction
Apoptosis, which is characterized by DNA-fragmentation,
nuclear condensation, alterations in pro-apoptotic proteins
levels, such as Bad, and release of mitochondrial cytochrome
c into the cytoplasm, may contribute to many cardiac
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Fig. 1 DNA fragmentation was induced by Ang II and/or IGF-I re-
ceptor antibody. H9c2 cells were cultured in serum-free medium as
negative control for overnight then treated with Ang II (10−8 M) and/or
IGF-I receptor antibody (20, 40, 60 ng/ml). The incubation was contin-
ued for another 24 h, and then the cells were harvested, extracted, and
DNA fragmentation was determined. Cells were treated with ionomycin
(10−7 M) as positive control (n = 3)
disorders [1, 2]. An increase in levels of the pro-apoptotic
protein angiotensin II (Ang II) has been observed in hy-
pertension, coronary artery disease, left ventricular hyper-
trophy, and heart failure [3] and may function as a regu-
lator of apoptosis in cardiac tissues [1]. One pathway of
angiotensin II induced hypertrophy and apoptosis may be
calcium-calcineurin [4]. Besides, patients with diabetes mel-
litus often exhibit abnormalities in insulin-like growth fac-
tor (IGF)-I, such as reduced circulating levels of IGF-I [5]
and increased IGF-I resistance [6]. IGF-I has been found
to improve myocardial function, promote cardiac growth,
improve cardiac contractility, evoke ventricular remodeling,
and prevent heart failure [7]. IGF-I has also been found to
suppress myocardial apoptosis and exert an anti-apoptotic
effect in cardiac cells through the phosphatidylinositol 3-
kinase/Akt kinase pathway [8, 9]. The cardiac survival or
apoptotic levels appear to be directly related to the amount
of IGF-I expressed [10, 11]. However, while IGF-I and Ang
II seem to play a role in cardiac apoptosis, it is unknown
whether their combined effect is non-additive, sub-additive,
additive, or synergistic.
IGF-I receptor (R) can be activated by IGF-I, IGF-II,
and insulin at supraphysiological concentrations. The IGF
II is one of the ligands that share a common IGF-IR
signaling pathway [11, 12]. The IGF-IR signaling path-
way appears to play an important role in the suppression
of apoptosis in a variety of cells, including cardiac cells
[10, 11]. However, when the IGF-I pathway is blocked,
IGF-II may stimulate myocardiac cell hypertrophy through
the IGF-IIR signaling pathway [13], which includes Gi-
protein and calcium-calcineurin pathways [14, 15]. Although
the exact mechanism of myocardiac hypertrophy and apopto-
sis is not totally correlated, Angiotensin-II activate calcium-
calcineurin pathway is both involved in hypertrophy [16]
and apoptosis [17]. However, the apoptotic mechanism of
IGF-I and IGF-II is unclear. With regard to cardiac cell death,
it is unknown whether IGF-I resistance will increase IGF-
IIR and IGF-II protein products and further activate IGF-IIR
signaling via calcineurin pathway.
To clarify the answers to these questions, this study as-
sesses apoptosis of cultured cardiomyoblast H9c2 cells. IGF-
I deficiency and/or IGF-IR resistance was found to induce
cardiomyoblast apoptosis, which might have been caused by
an upregulation of IGF-II and IGF-IIR genes with its down-
stream calcineurin pathway activation. This apoptosis was
possibly synergistically augmented by Ang II.
Methods
Cell culture
H9c2 cells were obtained from American Type Culture
Collection (ATCC) and were cultured in Dulbecco’s mod-
ified essential medium supplemented with 10% fetal bovine
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serum, 2 mM glutamine,100 units/ml penicillin, 100 µg/ml
streptomycin, and 1 mM pyruvate in humidified air (CO2
5%) at 37◦C. H9c2 cells were cultured in serum-free
medium with minimal essential medium. for 12 h, and then
treated with or without Ang II (10−8 M) (Sigma Chemical
Co., St. Louis, MO, USA), antisense IGF-I (14 µM), antis-
ense IGF-II (14 µM), IGF-I receptor antibody (100 ng/ml)
(Neo Markers, Fremont, CA, USA) or IGF-II antibody
(100 ng/ml) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). The incubation was continued for another 24 h,
and then the cells were harvested and extracted for the
analysis.
Design and synthesis of IGF-I and IGF-II
oligonucleotides
The 15-mers of IGF-I and IGF-II antisense oligonucleotides
(AsONs) used in this study are known to target the trans-
lation initiation site of IGF-I and IGF-II mRNAs in rats,
and are complementary to nucleotides (5′-ATG TCG TCT
TCA CAT-3′ and 5′-ATG GGG ATC CCA GTG-3′). In
addition, the IGF-I sense oligonucleotides, which are the
same as nucleotides (5′-ATG TCG TCT TCA CAT-3′ and
5′-ATG GGG ATC CCA GTG-3′ were used as negative con-
trols The sequences had no similarity to other mammalian
genes. All antisense oligonucleotides were synthesized as
lyophilized powders and reconstituted in sterile, nuclease-
free Tris-EDTA buffer (10 mM Tris HCl, 1 mM EDTA, (pH
7.4)) and stored at −20◦C.
Transfection of H9c2 cells using LipofectAMINE
Cells were grown to 80% confluence in 100-mm dishes.
IGF-I or IGF-II oligonucleotides and l ipofectAMINE were
separately diluted in serum-free DMEM to 200-µl volumes,
mixed, and incubated at room temperature for 20 min. Cells
were washed twice with PBS and overlaid with 5 ml of serum
free DMEM to which the DNA-lipid complexes were added.
Fig. 2 Cardiomyoblast
apoptosis was synergistically
induced by Ang II and IGF-IR
antibody. H9c2 cells were
cultured in serum-free medium
for overnight and then treated
with Ang II (10−8 M) and/or
IGF-I receptor antibody
(100 ng/ml). The incubation was
continued for another 24 h.
DAPI (4,6-diamidino-
2-phenylindole) (1 µg/ml,
Fig. (a)) staining and cleaved
caspase 3 and TUNEL assay
(Fig. (b)) were determined.
Cells were treated with
ionomycin (4 × 10−8M) as
positive control. A, serum-free
medium; B, ionomycin; C, Ang
II; D, IGF-IR antibody; E, Ang
II plus IGF-IR antibody; F, the
quantitive results. The values
are the mean ± S.E. (n = 3). ∗,
P < 0.05; ∗∗, P < 0.01 versus
the cells treated with serum-free
medium. Arrow head indicated
the nuclei condensed cells. A
relative quantification of
caspase 3 on the basis of
α-tubulin was applied. Bars in
Fig. (b) represent the percentage
of TUNEL-positive cardiac
myocytes on the basis of stained
total cells by DAPI and indicate
mean values ± SE (n = 3)
(Continue on next page)
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Fig. 2 (Continued)
The cells were incubated at 37◦C for 6 h, at which time
the medium was replaced with DMEM-10% FBS. The cells
were harvested after 24 h.
Agarose gel electrophoresis for DNA fragmentation
H9c2 cells were lysed in 50 µl of lysis buffer (50 mM
Tris-HCl (pH 7.4), 20 mM EDTA, 1%IGEPAL-630) fol-
lowed by incubation with 1%SDS and 5 µg/µl RNase (Roche
Molecular Biochemicals, Mannheim, Germany) for 2 h at
56◦C and 2.5 µg/µl proteinase K (Roche) for 2 h at 37◦C.
Only fragmented DNA was extracted. DNA was ethanol-
precipitated and finally resuspended in distilled water. The
fragmented DNA was electrophoretically fractionated on
1.5% agarose gel and stained with ethidium bromide.
DAPI staining and TUNEL assay
After various treatments, H9c2 cells grown on 6 mm plate
were fixed with 4% paraformaldehyde solution for 30 min
at room temperature. After a rinse with phosphate-buffered
saline, the samples were first incubated with phalloidin-
rhodamine for 1 h and with Terminal Deoxynucleotide
Transferase-mediated dUTP Nick End Labeling (TUNEL)
reaction mixture containing terminal deoxynucleotidyl trans-
ferase and fluorescein isothiocyanate-dUTP (Roche Applied
Science, Indianapolis, IN, USA). The cells were also stained
with 1 ug/ml 4′,6-diamidine-2-phenylindole dihydrochlo-
ride (DAPI, Roche) for 30 min to detect cell nucleus by
UV light microscopic observations (blue). Samples were
analyzed in a drop of PBS under a fluorescence and UV
light microscope at this state, respectively. Use an exci-
tation wavelength in the range of 450–500 nm and de-
tection in the range of 515–565 nm (green). The num-
ber of TUNEL-positive cardiac myocytes and number of
apoptotic bodies were determined by counting 3 × 105 car-
diac myocytes. All morphometric measurements were per-
formed by at least two independent individuals in a blinded
manner.
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Fig. 3 The amount of pro-apototic Bad protein and the release of
cytochrome c were increased by Ang II and IGF-IR antibody. H9c2
cells were cultured in serum-free medium for overnight and then
treated with Ang II (10−8 M) and/or IGF-I receptor antibody (20,
40, 60 ng/ml). The incubation was continued for another 24 h, and
the cells were harvested and extracted for the Western Blot analy-
sis. Cells were treated with ionomycin (10−7 M) as positive control.
Bars represent the relative quantification of Bcl2, Bad, and released
cytochrome c on the basis of control level and indicate mean fold
change ± SE (n = 3). ∗∗ P < 0.01, significant differences be-
tween groups with vs. without Ang II administration, #P < 0.01, sig-
nificant differences between IGF-IR groups with vs. without Ang II
administration
Western blot analysis
Cultured H9c2 cells were scraped and washed once with
phosphate-buffered saline. Cell suspension was then spun
down, and cell pellets were lysed for 30 min in lysis buffer
(50 mM Tris (pH 7.5), 0.5 M NaCl, 1.0 mM EDTA (pH 7.5),
10% glycerol, 1 mM BME, 1% IGEPAL-630 and proteinase
inhibitor cocktail (Roche)) and spun down 12,000 rpm for
10 min in an Eppendorf tube. Proteins were then separated
in 12% gradient SDS-PAGE and transferred to nitrocellu-
lose membranes. Nonspecific protein binding was stopped
in blocking buffer (5% milk, 20 mM Tris-HCl, pH 7.6,
150 mM NaCl, and 0.1% Tween 20) and blotted with specific
antibodies of caspase 3, caspase 9 (Santa Cruz Biotechnol-
ogy), Bcl2, Bad (BD Biosciences, Heidelberg, Germany),
p-Bad, and cytochrome c (Cell Signaling Technology, Bev-
erly, MA, USA) in the blocking buffer at 4◦C overnight. For
repeated blotting, nitrocellulose membranes were stripped
with Restore Western blot stripping buffer (Pierce Biotech-
nology, Inc, Rockford, IL, USA) at room temperature for
30 min.
To detect cytochrome c, cells were suspended in a buffer
(50 mM Tris (pH 7.5), 0.5 M NaCl, 1.0 mM EDTA (pH
7.5), 10% glycerol and proteinase inhibitor cocktail ta-
ble (Roche) for 3 min on ice, homogenized by 40 strokes
in a Dounce homogenizer, and centrifuged at 12,000 rpm
for 15 min. The supernatant was the cytosol fraction; the
pellet was resuspended in lysis buffer as the membrane
fraction.
Statistical analysis
Statistical differences were assessed by one way-ANOVA.
P < 0.05 was considered statistically significant. Data were
expressed as the mean ± SEM.
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Results
Apoptosis measured by DNA fragmentation was
induced by Ang II and/or IGF-IR antibody
To clarify whether cardiomyoblast apoptosis was induced
by Ang II and/or IGF-IR antibody, DNA fragmentations
were measured with or without administration of Ang II
(10−8 M) and/or IGF-I receptor antibody (20, 40, 60 ng/ml).
DNA ladder formation revealed that cardiac H9c2 cell un-
derwent DNA fragmentation when exposed to either Ang
II (10−8 M) or IGF-IR antibody (20, 40, and 60 ng/ml),
compared to the negative and positive controls (Fig. 1).
We observed a synergistic effect rather than additive ef-
fect on DNA fragmentation with the combination of Ang
II (10−8 M) and IGF-IR antibody (20, 40, and 60 ng/ml)
Fig. 4 (a) The IGF-II and IGF-IIR protein products were induced
by antisense IGF-I, IGF-IR antibody or IGF-I antibody. H9c2 cells
cultured in serum-free medium for overnight then treated with anti-
sense IGF-I (14 µM) and sense IGF-I (14 µM) as a negative con-
trol, as well as IGF-I receptor antibody (100 ng/ml), IGF-I antibody
(100 ng/ml), and non-specific IgG (100 ng/ml) as a control antibody.
The incubation was continued for another 24 h, and then the cells were
harvested and extracted for the Western Blot analysis. Bars represent
the relative quantification of IGF-II and IGF-II receptor on the basis
of control level and indicate mean fold change ± SE (n = 4). ∗∗ P <
0.01, significant differences from control group. (b) Antisense IGF-I
inhibit the IGF-I protein products. H9c2 cells cultured in serum-free
medium for overnight then treated with sense IGF-I (14 µM), antisense
IGF-I (7 µM) and antisense IGF-I (14 µM). Bars represent the rela-
tive quantification of IGF-I on the basis of control level and indicate
mean fold change ± SE (n = 4). ∗∗ P < 0.01, significant differences
from control group. (c) Antisense IGF-I and IGF-I antibody inhibit
the phosphorylated Akt and Akt protein products. H9c2 cells cultured
in serum-free medium for overnight then treated with antisense IGF-I
(7 µM and 14 µM) and IGF-I antibody (20, 50, 100 ng/ml). Bars repre-
sent the relative quantification of phosphorylated Akt and Akt protein
products on the basis of control level and indicate mean fold change
± SE (n = 4). ∗∗ P < 0.01, significant differences from control group
(continue on next page)
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Fig. 4 (Continued)
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(Fig. 1). In addition, the strength of the synergistic effect on
DNA fragmentation was dependent on the dosage of IGF-IR
antibody (20, 40, and 60 ng/ml). The higher the concentra-
tions of IGF-IR antibody, the more the DNA fragmentation
(Fig. 1).
Apoptosis measured by condensed nuclei with DAPI
staining and TUNEL assay was synergistically induced
by Ang II and IGF-IR antibody
To clarify whether cardiomyoblast apoptosis was induced by
Ang II and/or IGF-IR antibody, DAPI staining and TUNEL
assay were measured with or without administration of Ang
II (10−8 M) and/or IGF-I receptor antibody (100 ng/ml).
The condensation of nuclei stained with DAPI, indicating
cell apoptosis, was significantly (P < 0.05) increased by 3%
after administration of Ang II (10−8 M), and by 5% after ad-
ministration of IGF-IR antibody (100 ng/ml) in H9c2 cells,
compared to the negative control (Fig. 2). We observed a
higher condensation of nuclei when Ang II (10−8 M) and
IGF-IR antibody (100 ng/ml) were combined, compared to
the negative control (Fig. 2). This indicated that they ex-
erted a synergistic rather than an additive effect on cell
apoptosis.
The amount of pro-apoptotic Bad protein and the
release of cytochrome c were increased by Ang II and
IGF-IR antibody
The clarify whether mitochondrial dependent apoptotic path-
way was indused by Ang II and/or IGF-IR antibody, the
protein product of Bcl2, Bad, and cytosolic cytochrome c
were measured by Western Blotting with or without admin-
istration of Ang II (10−8 M) and/or IGF-I receptor antibody
(20, 40, 60 ng/ml). Western blot analysis revealed that the
expression of Bad protein and the release of cytochrome c
both increased in H9c2 after administration of either Ang
II (10−8 M) or IGF-IR antibody (20, 40, and 60 ng/ml),
compared to negative and positive controls (Fig. 3). We ob-
served a synergistic increase in production of Bad protein
or release of cytochrome c when Ang II (10−8 M) and
IGF-IR antibody (20, 40, and 60 ng/ml) were combined
(Fig. 3).
IGF-IIR and IGF-II protein products were increased by
IGF-I deficiencies or IGF-IR resistance
To clarify whether IGF-II, IGF-II receptor was up-regulated
by IGF-I deficiencies or IGF-IR resistance, the protein prod-
uct of IGF-II and IGF-II receptor were measured by West-
ern Blotting with administration of antisense IGF-I, IGF-I
antibody, IGF-I receptor antibody. Western blot analysis re-
vealed that the IGF-IIR and IGF-II protein products were in-
creased in H9c2 cells treated with antisense IGF-I (14 µM),
IGF-IR antibody (100 ng/ml), or IGF-I antibody (100 ng/ml),
whereas the IGF-IIR and IGF-II protein products were
not affected by the treatment of sense IGF-I (14 µM)
and non-specific IgG (a control antibody, 100 ng/ml)
(Fig. 4(a)).
To confirm the effects of antisense IGFI on IGF-I, the
protein product of IGF-I were measured after administration
of antisense IGF-I. The amount of IGF-I protein products
in H9c2 cells was not changed by sense IGF-I (14 µM)
but was reduced by antisense IGF-I (7 µM and 14 µM)
(Fig. 4(b)).
To clarify the activity of PI3 K-Akt pathway were
affected by IGF-I deficiencies, the protein products
of Akt were measured by Western Blotting with ad-
ministration of antisense IGF-I, IGF-I antibody. The
phosphorylated Akt protein products were significantly re-
duced by antisense IGF-I (7 µM and 14 µM) and IGF-I
antibody (20, 50, 100 ng/ml) in a dose-dependent manner
(Fig. 4(c)).
Apoptosis induced by impaired IGF-I signaling or
impaired IGF-I signaling plus Ang II was inhibited by
antisense IGF-II or IGF-II antibody
To clarify whether cardiomyoblast apoptosis induced by
impaired IGF-I signaling or impaired IGF-I signaling plus
Ang II was inhibited by antisense IGF-II or IGF-II antibody,
DAPI staining, TUNEL assay, and active caspase 9 and 3
were measured with or without administration of Ang II
(10−8 M), antisense IGF-I, IGF-I receptor antibody, antisense
IGF-II, and/or IGF-II antibody. The condensation of nuclei
stained with DAPI (Fig. 5(a)), TUNEL assay, (Fig. 5(b)), the
activated forms of caspase 9 and caspase 3 (Fig. 5(c)), all of
which indicating apoptosis, were significantly increased in
cardiac H9c2 cells after administrations of antisense IGF-I
(14 µM) only, after administration of antisense IGF-I plus
Ang II (10−8 M), and administration of IGF-IR antibody
(100 ng/ml) plus Ang II (10−8 M) (Fig. 5(a–c)). On the
other side, the increased condensations of the same nuclei
(Fig. 5(a)), the TUNEL positive cells (Fig. 5(b)), the in-
creased activated forms of caspase 9 and caspase 3 (Fig. 5(c)),
caused by administrations of antisense IGF-I (14 µM) only,
administration of antisense IGF-I plus Ang II (10−8 M), and
administration of IGF-IR antibody (100 ng/ml) plus Ang II
(10−8 M) were significantly (P < 0.05) decreased after addi-
tional administration of antisense IGF-II (14 µM) and IGF-II
antibody (100 ng/ml) in the cardiac H9c2 cells, respectively
(Fig. 5(a–c)).
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Bad protein products and the release of
cytochrome c induced by Ang II plus IGF-I
antibody or IGF-IR antibody were reduced by IGF-II
antibody
To clarify whether synergistic cardiomyoblast apoptosis in-
duced by angiotensin II plus impaired IGF-I signaling was
regulated by IGF-II, the protein products of Bad and the re-
lease of cytochrome c were measured by Western Blotting
with administration of Ang II (10−8 M) plus antisense IGF–I
and IGF-I antibody as well as with or without administra-
tion of IGF-II antibody. Western blot analysis showed that
the amount of Bad protein and the release of cytochrome
c were both increased in H9c2 after administration of ei-
ther Ang II (10−8 M) plus anti-sense IGF-I (14 µM) or
after the administration of Ang II (10−8 M) plus IGF-IR
antibody (100 ng/ml) (Fig. 6). The increases in Bad pro-
tein products and in cytochrome c release induced by ei-
ther Ang II (10−8 M) plus anti-sense IGF-I (14 µM) or
by Ang II (10−8 M) plus IGF-IR antibody (100 ng/ml) were
reduced by the administration of IGF-II antibody (100 ng/ml)
(Fig. 6).
Fig. 5 (a, b) Apoptosis induced by Ang II alone or plus antisense
IGF-I and/or IGF-IR antibody was inhibited by antisense IGF-II and
IGF-II antibody. H9c2 cells were treated with or without antisense IGF-
I (14 µM), IGF-I receptor antibody (100 ng/ml), Ang II (10−8 M),
antisense IGF-II (14 µM), or IGF-II antibody (100 ng/ml). DAPI
(4,6-diamidino-2-phenylindole) and TUNEL assay were determined.
A, serum free; B, antisense IGF-I; C, antisense IGF-I plus antisense
IGF-II; D, anti-sense IGF-I plus Ang II; E, antisense IGF-I plus Ang
II plus IGF-II antibody; F, IGF-IR anti-body plus Ang II; G, IGF-
IR antibody plus Ang II plus IGF-II antibody. The values are the
mean ± S.E. (n = 3, n = 3). ∗P < 0.05; ∗∗P < 0.01 represent
significantly different when versus the cells treated with serum-free
medium. #P < 0.05; ##P < 0.01 represent the antisense IGF-II or
IGF-II antibody effects. Arrow head indicated the nuclei condensed
cells. (c) Pro-Apoptosis protein, activated forms of caspase 9 and 3
measured by Western Blotting were re-confirmed. Bars represent the
relative quantification of activated forms of caspase 9 and caspase 3
protein products on the basis of control level and indicate mean fold
change ± SE (n = 4). ∗∗P < 0.01, significant differences from control
group. ##P < 0.01 significant effects of the antisense IGF-II or IGF-II
antibody (Continue on next page)
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Fig. 5 (Continued)
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Fig. 6 The increase of Bad
protein products and
cytochrome c release induced by
antisense IGF-I plus Ang II or
IGF-IR antibody plus Ang II,
were reduced by IGF-II
antibody treatment. H9c2 cells
cultured in serum-free medium
for overnight then treated with
antisense IGF-I (14 µM) plus
Ang II (10−8 M), or IGF-I
receptor antibody (100 ng/ml)
plus Ang II (10−8 M), with or
without IGF-II antibody
(100 ng/ml). The incubation was
continued for another 24 h, and
then the cells were harvested
and extracted for the Western
Blot analysis. Bars represent the
relative quantification of Bcl2,
Bad, and released cytochrome c
protein products on the basis of
control level and indicate mean
fold change ± SE (n = 4). ∗∗P
< 0.01, significant differences
from control group.##P < 0.01
significant effects of the IGF-II
antibody
The synergistic DNA fragmentation
induced by Ang II plus impaired IGF-I
signaling was remarkably attenuated by the
calcineurin inhibitor
To clarify whether cardiomyoblast apoptosis induced by an-
giotensin II plus impaired IGF-I signaling was regulated by
calcineurin pathway, DNA fragmentation and active caspase
3 were measured with administration of Ang II plus anti-
sense IGF-I and IGF-I antibody as well as with or without
administration of calcineurin inhibitor (CsA and/or FK-506).
H9c2 cardiomyoblast cells underwent DNA fragmentation
and increase the active caspase 3 when exposed to either
Ang II (10−8 M) and antisense IGF-I (14 mM) or Ang II
(10−8 M) and IGF-IR antibody (100 ng/ml). The fragmen-
tation was remarkably attenuated by the administration of
CsA (1 µM) (Fig. 7(a) and (b)). A combination of IGF-IR
antibody (100 ng/ml) and Ang II (10−8 M) also had an effect
on DNA fragmentation (Fig. 7(a)) and increase the active
caspase 3 (Fig. 7(b)), which were attenuated by the admin-
istration of CsA (1 µM) (Fig. 7(a) and (b)) and FK-506
(Fig. 7(b)).
IGF-IR antibody plus Ang II or IGF-IR antibody plus
IGF-II induced activated Bad protein products and the
release of cytochrome c were remarkably attenuated by
the CsA
To clarify the pathway from phosphorylated Bad to release
of cytochrome c induced by IGF-I receptor resistance with
and without angiotensin II was regulated by calcineurin path-
way, the protein products of phosphorylated Bad, Bad, and
cytosolic cytochrome c were measured. Western blot analy-
sis showed that after the administration of IGF-IR antibody
(100 ng/ml) plus Ang II (10−8 M) or after the administra-
tion of IGF-IR antibody plus IGF-II (100 ng/ml) to H9c2
cells, there was a decrease in the amount of phosphorylated
Bad protein and an increase in Bad protein and the released
cytochrome c. These changes were remarkably attenuated
by the administration of CsA(1 µM) (Fig. 8).
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Discussion
Our main findings can be summarized as follows: (1) By ob-
serving DNA fragmentation, stained cell nuclei and TUNEL
assay in H9c2 cells, we found a synergistic effect on car-
diomyoblast apoptotic process induced by IGF-I deficiency
Fig. 7 The synergistic DNA fragmentation and active caspase 3 in-
duced by Ang II and IGF-IR antibody was remarkably attenuated by
calcineurin inhibitor. H9c2 cells cultured in serum-free medium for
overnight then treated with Ang II (10−8 M) plus antisense IGF-I
(14 µM), IGF-I receptor antibody (100 ng/ml), or IGF-II (100 ng/ml),
with or without cyclosporine A (CsA, calcineurin inhibitor, 1 µM)
and/or FK-506 (10 µ/ml). The incubation was continued for another
24 h, and then the cells were harvested, extracted, and DNA fragmen-
tation (n = 3) and active caspase 3 was determined (n = 4)
and/or IGF-IR resistance as well as Ang II (2); Western Blot
analysis showed that the protein production of IGF-II and
IGF-II receptor appeared to be upregulated by IGF-I defi-
ciency and/or IGF-IR resistance in H9c2 cells, respectively
(3); after blocking IGF-I and/or IGF-IR, the Ang II-induced
increases in Bad pro-apoptotic protein and the release of cy-
tochrome c were reduced by IGF-II antibody treatment; and
[4] the apoptotic DNA fragmentation and active caspase 3
induced by Ang II plus IGF-IR antibody was attenuated by
the calcineurin inhibitor, CsA and/or FK-506. After integrat-
ing our current findings into previously proposed apoptotic
theory, our proposed hypothesis in cardiomyoblast apoptosis
was presented in Fig. 9.
Angiotensin II has been reported to be involved in the
stimulation of cardiac apoptosis in essential hypertension
without major hemodynamic consequences [18, 19]. In the
current study, when Ang II and IGF-I antibody or Ang II and
IGF-IR antibody were co-administered, we observed a syn-
ergistic effect on cardiomyoblast apoptosis by the character-
istic DNA fragmentation, DAPI stained cell nuclei, TUNEL
positive cells, increased pro-apoptotic Bad, activated
caspase 9, activated caspase 3 protein products, and the
release of cytochrome c. This finding suggests that the
stimulation of cardiac apoptosis will be exacerbated in
hypertensive patients who have IGF-I deficiencies and/or
IGF-IR resistances. IGF-I is an important survival growth
factor that has been found to suppress myocardial apoptosis
and exert an anti-apoptotic effect through the phosphatidyli-
nositol 3-kinase/Akt kinase pathway and MAPK pathway in
cardiomyoblast cells (Fig. 9) [8, 9]. Such findings indirectly
support our findings that IGF-I deficiency or IGF-IR resis-
tance, which block the IGF-I survival pathway, exacerbate
cardiac apoptosis (Fig. 9). In addition, our data showed that
higher concentrations of IGF-IR antibody caused more DNA
fragmentation, Bad protein production, and cytochrome c
release. These increases suggest the severity of angiotensin
II-induced cardiomyoblast apoptosis is related to the severity
of IGF-I deficiency and/or IGF-IR resistance. Our findings
further support the previous concept that cardiomyoblast
apoptotic levels are directly related to the amount of IGF-I
deficiency and/or IGF-IR resistance [11].
The upregulation of IGF-II and IGF-II receptor in car-
diomyoblast cells in this study appeared to be induced by
IGF-I deficiency and/or IGF-IR resistance by treating with
antisense IGF-I, IGF-IR antibody, or IGF-I antibody. One of
our previous reports found a similar upregulation of IGF-II
and IGF-IIR mRNA level in cultured adult rat ventricular
cardiac cells after administration of IGF-I or IGF-IR anti-
body [13]. The IGF-II gene has been found to be expressed
at high levels during embryonic and fetal life and at low
levels in adult animals [20]. In one animal model used in an
experiment on coronary artery occlusion, the short pulses of
myocardial ischemia caused increased mRNA expression of
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Fig. 8 The synergistic
apoptosis measured by
phosphorylated Bad and Bad
protein products and
cytochrome c release induced by
Ang II and IGF-IR antibody was
remarkably attenuated by
calcineurin inhibitor. H9c2 cells
cultured in serum-free medium
for overnight then treated with
Ang II (10−8 M), IGF-I receptor
antibody (100 ng/ml), Ang II
(10−8 M) plus IGF-I receptor
antibody (100 ng/ml), with or
without cyclosporine A (CsA,
calcineurin inhibitor, 1 µM).
The incubation was continued
for another 24 h, and then the
cells were harvested, extracted,
and phosphorylated Bad and
Bad protein products and
cytochrome c release was
determined by Western Blotting.
Bars represent the relative
quantification of phosphorylated
Bad, Bad, and released
cytochrome c protein products
on the basis of control level and
indicate mean fold change ± SE
(n = 4). ∗∗P < 0.01, significant
differences from control group.
##P < 0.01 significant effects of
CsA
the IGF-II gene [21]. The transactivation and over-expression
of IGF-II gene in mice resulted in prenatal overgrowth and
disproportionate organ overgrowth including cardiac ab-
normalities [22]. However, the mechanism of IGF-II and
IGF-IIR regulated by IGF-I deficiency and/or IGF-IR resis-
tance in cardiomyoblast cells is still unclear.
In this study, the increased condensation of nuclei stained,
Bad, activated caspase 9, activated caspase 3 protein prod-
ucts, and the release of cytochrome c caused by impaired
IGF-I signaling and/or angiotensin II were inhibited by
the administration of antisense IGF-II and IGF-II antibody.
The IGF-II may activate Gi-2, a GTP binding protein, acti-
vate a calcium-permeable cation channel through a cell sur-
face IGF-II receptor, and further activate Bad pathway and
Bad-related apoptosis [17, 23] (Fig. 9). IGF-II and IGF-II re-
ceptor appear to be up regulated by IGF-I deficiency and/or
IGF-IR resistance and cardiomyoblast apoptosis induced
by + IGF-I signaling appear to be restored by antisense
IGF-II and IGF-II antibody. Therefore, we can speculate
that IGF-I deficiency and/or IGF-IR resistance induces
cardiomyoblast apoptosis and that the up regulation of IGF-II
and IGF-IIR genes with their downstream pathway activation
is augmented by Ang II (Fig. 9).
Since the synergistic effect of DNA fragmentation
induced by Ang II plus IGF-IR antibody was remarkably
attenuated by the calcineurin inhibitor, CsA, in the current
study, we conclude that calcium (Ca2+)-calcineurin is an
important candidate pathway for the synergistic apoptotic
effect of angiotensin II and IGF-I deficiency and/or IGF-IR
resistance in cardiomyoblast cells. Angiotensin II is thought
to activate calcium-calmodulin-dependent protein phos-
phatase calcineurin through Galphaq (Gα-q)/PLC signaling
transduction, which is mediated by permeability transition
pore formation and activation of the mitochondrial death
pathway (Fig. 9) [16, 24]. Calcium-calcineurin might further
dephosphorylate the transcription factor NFAT3, enabling it
to translocate to the nucleus and interact with GATA tran-
scription factor, resulting in synergistic activation of cardiac
transcription and cardiac pathological hypertrophy [16, 25].
Cardiac pathological hypertrophy is rapidly succeeded by
apoptotic cellular and molecular changes [24]. At the same
time, Ca2+/Calcineurin also dephosphorylates proapoptotic
Bcl-2 family protein, Bad, and induces cytochrome c release
from mitochondria to the cytosol, which further induces
caspases activation, and cardiac cell apoptosis (Fig. 9) [17,
24, 25]. However, the IGF-II has been shown to directly
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Fig. 9 The proposed hypothesis of IGF-I, IGF-II, and Angiotensin
II pathways in cardiomyoblast apoptosis relevant to this study. IGF-I
binding IGF-I receptors via intracellular signaling pathways involving
tyrosine kinase (TK) activity may exert an anti-apoptotic effect via
phosphatidylinositol 3-kinase (PI3 K) and Akt kinase (Akt)-dependent
Bad phosphorylation (Bad-p). Antisense IGF-I, IGF-I antibody, or
IGF-I receptor antibody not only blocked IGF-I survival pathway, but
also upregulated IGF-II and IGF-IIR (upper arrows) under IGF-IR re-
sistance. Although the mechanism of upregulation of IGF-II system
is still unclear, apoptosis induced by IGF-I resistance was inhibited
by antisense IGF-II or IGF-II antibody. IGF-II may bind IGF-II re-
ceptors via Gi, a GTP binding protein and further activate a calcium
(Ca2+)-calcineurin-mediated dephosphorylation of Bad, which may
further activate Bad-related apoptotic pathway. Angiotensin II (Ang
II) was also considered to activate a calcium-calcineurin-mediated de-
phosphorylation of Bad through G-protein-coupled receptors (GPCR),
Galphaq (Gα-q)/PLC signaling transduction. However, calcineurin in-
hibitor (cyclosporine A and FK-506) did attenuate the synergistic apop-
tosis induced by Ang II plus IGF-I resistance. Therefore, Ang II en-
hance IGF-IR resistant effect and exacerbate more severe cardiac apop-
tosis is somewhat mediated through the calcineurin activation. The
dotting-lines represent unknown pathways
induce hypertrophy in adult rat cardiac cells in a serum–free
medium as demonstrated by their increased size, total
protein synthesis, and transcription of muscle-specific genes
[26]. In addition to its activation of Gi-2 and calcium-
calcineurin through a cell surface IGF-II receptor, IGF-II
might, when the IGF-IR-dependent pathway is blocked,
induce hypertrophy in adult rat cardiac cells via another
two alternative pathways: an IGF-IR-dependent pathway
or a lysosome-dependent pathway [27]. Primary ventricle
myocytes culture can be used to confirm all these findings.
Conclusion and possible clinical application
We found that IGF-I deficiency and/or IGF-IR resistance
induced apoptosis in cardiomyoblast cells. The apoptosis,
which might have been caused by the upregulation of IGF-
II and IGF-IIR genes possibly activated the downstream
calcineurin pathway, was synergistically augmented by
Ang II. Our findings may raise a further question about
whether myocardial cell death in patients with hypertension
induced by Ang II and impaired IGF-I system is caused by
an upregulation of IGF-II system and calcineurin activity. In
diabetes, IGF-I receptor antibodies bind to the IGF-I recep-
tor at or near the IGF-I binding sites, inhibit IGF-I binding,
and probably cause IGF-I resistance [6]. Besides, the circu-
lating IGF-I levels and IGF-I function fall progressively with
aging [28]. Cardiovascular disease is reported to be a major
cause of morbidity and mortality in patients with diabetes
mellitus [29]. It has been suggested that specific vascular
and myocardiopathic alterations are responsible for the ex-
cessive cardiovascular morbidity and mortality in diabetes
[29]. Diabetic cardiac apoptosis may be viewed as an an-
giotensin II-dependent process, in which angiotensin II may
play a critical role in myocyte death and hypertrophy [30].
The cardiovascular alterations in patients with diabetes mel-
litus manifest themselves clinically as hypertension, coro-
nary heart disease, congestive heart failure and/or sudden
cardiac death [29, 30]. In order to prevent cardiovascular
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diseases in diabetes, it has been suggested that diabetic pa-
tients maintain excellent glycemic control, a normal blood
pressure control, and be taking an angiotensin-converting
enzyme inhibitor. Our findings may further suggest that di-
abetic patients maintain a normal IGF-I function and try to
prevent the upregulation of IGF-II system, such as IGF-I
supplement and/or IGF-II and calcineurin inhibitors. If this
can be done, then cardiomyoblast apoptosis might be inhib-
ited in diabetic patients with cardiovascular diseases. Further
animal or human studies are required to confirm the possi-
ble signaling pathways and the clinical applications of this
study.
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